The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 8, 2012, Pages 2736-2741

  Jin, Kideok ^a   Kong, Xiangjun ^b   Shah, Tariq ^a   Penet, Marie France ^a   Wildes, Flonne ^a   Sgroi, Dennis C ^c   Ma, Xiao Jun ^d   Huang, Yi ^a,i   Kallioniemi, Anne ^e   Landberg, Goran ^f   Bieche, Ivan ^g   Wu, Xinyan ^a   Lobie, Peter E ^h   Davidson, Nancy E ^a,i   Bhujwalla, Zaver M ^a   Zhu, Tao ^b   Sukumar, Saraswati ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d AviaraDx   (United States)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g INSTITUT CURIE   (France)

^h NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

ⁱ UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; PROTEIN HOXB7; PROTEIN TYROSINE KINASE; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CARCINOGENESIS; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG ACTIVITY; HUMAN; HUMAN CELL; MONOTHERAPY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84863115448     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1018859108     Document Type: Article

References (36)

1. Brown RJ, Davidson NE (2006) Adjuvant hormonal therapy for premenopausal women with breast cancer. Semin Oncol 33:657-663. (Pubitemid 44828125)
2. Jordan VC, Brodie AM (2007) Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72:7-25. (Pubitemid 46037765)
3. Gutierrez MC, et al. (2005) Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23:2469-2476. (Pubitemid 47050837)
4. Howell A, et al. (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 22:1605-1613. (Pubitemid 41079798)
5. Garcia-Fernàndez J (2005) The genesis and evolution of homeobox gene clusters. Nat Rev Genet 6:881-892.
6. Wu X, et al. (2006) HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res 66:9527-9534. (Pubitemid 44623651)
7. Carè A, et al. (2001) HOXB7: A key factor for tumor-associated angiogenic switch. Cancer Res 61:6532-6539. (Pubitemid 32783261)
8. Ackerstaff E, Gimi B, Artemov D, Bhujwalla ZM (2007) Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line. Neoplasia 9:222-235. (Pubitemid 46457239)
9. Bhujwalla ZM, et al. (2003) Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 9:355-362. (Pubitemid 36109752)
10. Lundberg AS, Hahn WC, Gupta P, Weinberg RA (2000) Genes involved in senescence and immortalization. Curr Opin Cell Biol 12:705-709.
11. Martin LA, et al. (2005) The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through downregulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer 12:1017-1036.
12. Nicholson RI, et al. (2005) Growth factor signalling networks inbreast cancer and resistance to endocrine agents: New therapeutic strategies. J Steroid Biochem Mol Biol 93:257-262. (Pubitemid 40602498)
13. Hiscox S, et al. (2006) Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer 118:290-301. (Pubitemid 41779067)
14. Jeng MH, et al. (1998) Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 139:4164-4174.
15. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC (2003) Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.JNatl Cancer Inst 95:1597-1608. (Pubitemid 37455927)
16. Gee JM, et al. (2006) Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocr Relat Cancer 13(Suppl 1):S77-S88. (Pubitemid 46219250)
17. Hynes NE, Lane HA (2005) ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 5:341-354. (Pubitemid 40637826)
18. Knowlden JM, et al. (2003) Elevated levels of epidermal growth factor receptor/ c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144:1032-1044. (Pubitemid 36262870)
19. Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI (2005) Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor. Endocrinology 146:4609-4618. (Pubitemid 41446598)
20. Britton DJ, et al. (2006) Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 96:131-146.
21. Nishi H, Nishi KH, Johnson AC (2002) Early Growth Response-1 gene mediates up-regulation of epidermal growth factor receptor expression during hypoxia. Cancer Res 62:827-834. (Pubitemid 34126960)
22. Hyman E, et al. (2002) Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 62:6240-6245. (Pubitemid 35244477)
23. Rydén L, et al.; South Swedish Breast Cancer Group; South-East Swedish Breast Cancer Group (2005) Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: A randomised, controlled trial with long-term follow-up. Eur J Cancer 41:256-264. (Pubitemid 40136540)
24. Ma XJ, et al. (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5:607-616.
25. Johnston SR, et al. (2003) Integration of signal transduction inhibitors with endocrine therapy: An approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 9:524S-532S. (Pubitemid 36105797)
26. Arpino G, et al. (2007) Treatment of human epidermal growth factor receptor 2- overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 99:694-705. (Pubitemid 47073531)
27. Jones HE, et al. (2005) Development of strategies for the use of anti-growth factor treatments. Endocr Relat Cancer 12(Suppl 1):S173-S182. (Pubitemid 41395424)
28. Kanda N, Watanabe S (2005) 17beta-estradiol enhances heparin-binding epidermal growth factor-like growth factor production in human keratinocytes. Am J Physiol Cell Physiol 288:C813-C823. (Pubitemid 40395059)
29. Ciarloni L, Mallepell S, Brisken C (2007) Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development. Proc Natl Acad Sci USA 104:5455-5460. (Pubitemid 47175701)
30. Saeki T, et al. (1991) Regulation by estrogen through the 5′-flanking region of the transforming growth factor alpha gene. Mol Endocrinol 5:1955-1963.
31. Polychronis A, et al. (2005) Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor- receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial. Lancet Oncol 6:383-391. (Pubitemid 40753744)
32. Chen H, et al. (2008) Hoxb7 inhibits transgenic HER-2/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis. Cancer Res 68:3637-3644.
33. Carroll JS, et al. (2005) Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122:33-43. (Pubitemid 40977938)
34. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS (2011) FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 43:27-33.
35. Hurtado A, et al. (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456:663-666.
36. Pärssinen J, Kuukasjärvi T, Karhu R, Kallioniemi A (2007) High-level amplification at 17q23 leads to coordinated overexpression of multiple adjacent genes in breast cancer. Br J Cancer 96:1258-1264. (Pubitemid 46625069)